Advertisement

How to Build the Trust of Your Referring Physicians

  • Stuart Jon SpechlerEmail author
Chapter

Abstract

Patients with typical gastroesophageal reflux disease (GERD) symptoms who respond well to medical therapy typically are not referred for antireflux surgery. The surgeon is far more likely to see referrals for patients with atypical GERD symptoms that have not responded to treatment with proton pump inhibitors (PPIs). Although the PPIs are far from perfect in eliminating GERD symptoms, failure to respond to PPIs is a red flag that should alert the astute clinician that GERD might not be the cause of symptoms. Excellent surgical outcomes will go a long way in building the trust of the referring physician, and the best way to achieve those excellent outcomes is to ensure that the “refractory GERD symptoms” prompting the surgical referral are indeed due to GERD. This can be accomplished by a careful preoperative work-up, which is outlined in this chapter. In preoperative discussions with the patient, the surgeon will build trust in the referring physician by being open in presenting the risks and benefits of alternative treatment options, by realistically appraising the operation’s anticipated benefits and by clearly presenting the potential complications of fundoplication. In these discussions, the surgeon should not exaggerate the risk of GERD complications like esophageal adenocarcinoma, nor make unsubstantiated claims that fundoplication is superior to medical therapy in preventing these complications. Such tactics are often construed, appropriately or not, as attempts to frighten a patient into an operation, tactics that are not likely to instill trust in the referring physician.

Keywords

Gastroesophageal reflux Reflux esophagitis Proton pump inhibitors Antireflux surgery Fundoplication Barrett’s esophagus Esophageal adenocarcinoma Multichannel intraluminal impedance monitoring Esophageal pH monitoring Esophageal manometry 

References

  1. 1.
    Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.CrossRefPubMedGoogle Scholar
  2. 2.
    Dent J, Hetzel DJ, MacKinnon MA, Reed WD, Narielvala FM. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol Suppl. 1989;166:76–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson DA, Oldfield IV EC. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W. Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA. 2001;285:2331–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engström C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A, Nordic GERD Study Group. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7:1292–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Spechler SJ. The management of patients who have “failed” antireflux surgery. Am J Gastroenterol. 2004;99:552–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg. 2003;237:291–8.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol. 2003;98:2390–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Chang EY, Morris CD, Seltman AK, O’Rourke RW, Chan BK, Hunter JG, Jobe BA. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg. 2007;246:11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ye W, Chow WH, Lagergren J, Yin L, Nyrén O. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Tran T, Spechler SJ, El-Serag HB. Fundoplication and the risk of cancer in gastroesophageal reflux disease: a veterans affairs cohort study. Am J Gastroenterol. 2005;100:1002–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138:1297–301.CrossRefPubMedGoogle Scholar
  13. 13.
    Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Tan S, DeMeester SR, Hagen JA, Bremner CG. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3:292–300.CrossRefPubMedGoogle Scholar
  14. 14.
    Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Spechler SJ. Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol. 2009;7:1264–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, DeVault K, Fass R, Gyawali CP, Kahrilas PJ, Lacy BE, Pandolfino JE, Patti MG, Swanstrom LL, Kurian AA, Vela MF, Vaezi M, DeMeester TR. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg. 2013;217:586–97.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of MedicineEsophageal Diseases Center, VA North Texas Healthcare System, University of Texas Southwestern Medical CenterDallasUSA
  2. 2.Division of Gastroenterology and Hepatology (111B1)Dallas VA Medical CenterDallasUSA

Personalised recommendations